Trials / Completed
CompletedNCT00159861
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sildenafil citrate |
Timeline
- Start date
- 2003-07-01
- Completion
- 2006-01-01
- First posted
- 2005-09-12
- Last updated
- 2021-02-01
- Results posted
- 2011-01-12
Locations
52 sites across 11 countries: United States, Belgium, Canada, Czechia, Denmark, France, Israel, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00159861. Inclusion in this directory is not an endorsement.